Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis.

Conclusion: Ozanimod appears to have a favorable benefit-risk profile versus fingolimod. PMID: 31948278 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research